Member Info for ChrisToffer

https://www.fiercepharma.com/pharma/pfizer-faces-doj-sec-foreign-bribery-probes-for-china-russia-operations

I'm down the same Tyla. Not easy but SNG will still out licence the drug at some point and their fully funded for phase 3. That's an incredibly valuable prospect regardless of covid or vaccines.

Hahaha

94 people of 42000 is less than 0.22%. How is that correct Doc?

The news today is good for mankind because it will go someway to eventually slowing community transmission.

A successful vaccine may lower the need and value of SNG001 but it will still be worth billions because it treats those most at risk.

Never sold a bean. The markets reaction was the same for SNG, ODX, AVCT and even NCYT who are still selling PCR test quicker than they can make them. No sense applied to any particular share dropping which tells us that it is all driven by sentiment and nothing more.

Tough to watch but the fundamentals haven't changed!

That french trial is not Synairgen.

Thanks Matt, I would add;

-last patient dosed in home arm of the p2 trial
-subsequent readout

Retrosec, you're absolutely correct. Infact, the presentation that dumbpunter is sharing to support his statements was the very presentation used to raise £80 million.

"the placebo group caught up with the treatment group and there was no difference in final result."

3 Patients in the placebo group unfortunately did not 'catch up'.

Hi Badsterman, That clinical trial is not Synairgen. It is a french trial using inhaled INF-1B .

"you sit here and all you do is slate anyone who doesn't agree with you." only the gob****es Parsley!

DP being schooled on BB etiquette by Parsley! Hahaha

Wow Dumbpunter, you've really changed your tune! If they couldn't get anyone interested how did they raise £80 million in a matter of hours? I think you're trying to convince yourself that you made the right decision on selling out. Time will tell.

"Forget about the p2 data read out; its all about the results of p3 now (to quote Synairgen themselves)."

Dumbpunter, can you point us to the Synairgen quote that says that? I'm sure the home arm of the P2 trial is still in focus for the company. They've outsourced the running of the P3 trial so the 2 are not mutually exclusive.

Scinv, you've posted that RM is a crook amd now you're saying there are many here who are delusional and absurd.

Scinv, youre like a dog with a bone, give it up man!

*aren't

The company did put together a presentation for the placing. Experts around the world will also work for big pharma and the regulators who will see the entire dataset. Peer review will come and I do think it will add value however it won't inform the critical path (route to approval/market), which is why the company are making a big thing out of it.

What benefit would a non-peer reviewed publication have served?

A positive peer review and publication will of course underline the july results. The company's confidence in the quality if their dataset would suggest that they'll also be confident in the peer review. Ultimately though, its going to say something along the lines of, 'this data supports the need for further investigation of SNG001 in the treatment of hoslitalised COVID patients.' Theyre already moving on with a p3 so the P2 peer review, though welcome, is a little academic.